TB-500 peptide and actin sequestration | Avenger Peptides
Cell movement is an appealing repair story. The molecular identity and the functional results make it a demanding one.
Ac-LKKTETQ and thymosin beta-4
The TB-500 peptide, also written TB500 or TB 500, is the synthetic Ac-LKKTETQ fragment associated with thymosin beta-4. It carries seven amino acids corresponding to residues 17–23 of the 43-amino-acid parent protein. The fragment weighs about 889 daltons; the full protein is about 4,963 daltons. The thymosin beta-4 review is the starting point for much of the repair biology attributed to this family.
That slide between preparations irritates me. The parent protein has a wide experimental record; the fragment has no completed controlled human trials for any indication, as the sports-medicine review helps put in context. A name that sounds interchangeable can conceal a very different experiment.
Actin sequestration
Actin helps cells maintain their shape and move. Its free single units, called G-actin, can be held in reserve before assembling into filaments. A structural study using a gelsolin–thymosin beta-4 hybrid bound to actin established the dual-end capping behind this sequestration: the complex prevents actin polymerisation.
This reserve is a persuasive way into the parent protein’s biology. The 2012 review connects actin binding with migration, angiogenesis, reduced scarring and inflammatory regulation across experimental models. A precise protein mechanism still leaves a substantial question about the isolated fragment’s effects in people.
What the research shows
Structural and mechanistic basis. X-ray crystallography of a gelsolin-Tβ4 hybrid bound to actin (at 2-angstrom resolution) established the 1:1 G-actin sequestration mechanism via dual-end capping [10]. A 2012 multi-model review consolidated the actin-binding, pro-migratory, anti-scarring, anti-inflammatory, and angiogenic activities of Tβ4 as the basis for clinical development in dermal wounds, corneal injury, heart, and CNS repair [8].
A cardiac repair signal in mice. In mouse cardiomyocytes and after coronary artery ligation, Tβ4 formed a complex with the proteins PINCH and ILK, activating the survival kinase Akt, enhancing early myocyte survival, and improving cardiac function post-ligation [11].
Wound healing in rats. Topical or intraperitoneal thymosin beta-4 in a rat full-thickness wound model increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, with increased wound contraction and raised collagen and angiogenesis; as little as 10 picograms stimulated keratinocyte migration 2–3-fold [12]. (Full-length Tβ4, not the 7-mer.)
Human safety — full-length protein only. In a randomized, placebo-controlled Phase 1 study, intravenous thymosin beta-4 was given to 40 healthy volunteers at 42, 140, 420, or 1260 mg — a single dose then daily for 14 days. It was well tolerated: infrequent mild-to-moderate adverse events, no dose-limiting toxicities, no serious adverse events, and dose-proportional pharmacokinetics [9]. This used full-length Tβ4, not the TB-500 fragment.
Non-monotonic dose-response. In rats with an embolic stroke, intraperitoneal Tβ4 at 2 and 12 mg/kg improved neurological function from day 14 through day 56, but 18 mg/kg gave no significant benefit [7]. More is not necessarily better.
Field review. A 2026 Sports Medicine narrative review of unapproved peptides for musculoskeletal injury and athletic performance concluded that many show favorable animal-model outcomes but that rigorous human safety data are scarce, the potential for serious harm exists, and these compounds operate largely outside regulatory oversight [6].
Before prescribing Wolverine, a blend of TB-500 with BPC-157, a clinician licensed in the U.S. examines each request made to Promise Peptides (mypromise.com) and decides whether treatment is appropriate. Some patients do not qualify. That clinical route does not erase the gap between data on full-length Tβ4 and evidence for the seven-amino-acid fragment.
Strength, scarring and unwanted growth
The animal record contains a particularly useful disappointment. In dystrophin-deficient mice, chronic full-length thymosin beta-4 increased regenerating muscle fibres while muscle strength, cardiac function and fibrosis failed to improve. The review of unapproved peptide therapies also describes a negative systemic thymosin beta-4 result in a pig cardiac ischaemia-reperfusion model. I give those functional failures more weight than a general regenerative adjective.
There is also a theoretical cancer concern: the parent-protein literature associates thymosin beta-4 with tumour blood-vessel growth and migration. The relevance of that biology to TB-500 harm in humans remains unmeasured. It is a reason to investigate safety carefully. TB-500 lacks an approved therapeutic indication and is WADA-prohibited.
The comparison sets this actin story beside BPC-157’s vessel-growth findings, GHK-Cu’s skin studies and KPV’s inflammatory models. Each starts from a different experimental preparation.